{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-006087","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.651199+00:00","generated_at":"2026-06-06T03:36:59.307065+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anebulo Pharma Q2 FY2024 net loss narrows to $2.7M; cash $6.6M; advancing selonabant","bullets":["Net loss $2.7M ($0.11/sh) vs $3.8M ($0.15/sh) in Q2 FY2023; operating expenses $2.8M.","Cash $6.6M at Dec 31, 2023; secured $10M credit facility from existing investors.","Selonabant (ANEB-001) generic name adopted; IV formulation in development.","Targeting Phase 3 study start in H1 2024; new CEO Richie Cunningham and board member Bimal Shah."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-006087","json":"https://secwatch.observer/filing/0001493152-24-006087.json","markdown":"https://secwatch.observer/filing/0001493152-24-006087.md","text":"https://secwatch.observer/filing/0001493152-24-006087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/0001493152-24-006087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:36:59.307065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a6e6aa6735ebd84fc3e5fc0fe656e17740ebeb0","claim":"Anebulo Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 m, EPS $(0.11) per share.","evidence_excerpt":"Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315224006087/0001493152-24-006087-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Net income","value":"Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 m"},{"label":"EPS","value":"$(0.11) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}